Coherus Biosciences announced today that it has entered into a $75 million senior secured credit facility agreement with Healthcare Royalty Partners.  According to the press release, the funds will be used to “accelerate and enhance the manufacture and sale of UDENYCA (pegfilgrastim-cbqv).”  The press release also confirms that UDENYCA launched in the United States on January 3, 2019, as we reported was being planned following the District of Delaware’s dismissal of Amgen’s patent infringement complaint against Coherus.